Estimating rates of multiple gestation pregnancies: Sample size calculation from the assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Wayne Sate University, 3800 Woodward Avenue, Suite 320, Detroit, MI 48201, USA.
Contemporary clinical trials (Impact Factor: 1.99). 07/2011; 32(6):902-8. DOI: 10.1016/j.cct.2011.07.009
Source: PubMed

ABSTRACT Infertility afflicts 15% of couples who wish to conceive. Despite intensive evaluation of both male and female partners, the etiology may remain unknown leading to a diagnosis of unexplained infertility. For such couples, treatment often entails ovulation induction (OI) with fertility medications coupled with intrauterine insemination. Complications of this therapy include ovarian hyperstimulation syndrome and creation of multiple gestation pregnancies, which can be complicated by preterm labor and delivery, and the associated neonatal morbidity and expense of care for preterm infants. The Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS) study is designed to assess whether OI in couples with unexplained infertility with an aromatase inhibitor produces mono-follicular development in most cycles, thereby reducing multiple gestations while maintaining a comparable pregnancy success rate to that achieved by OI with either gonadotropins or clomiphene citrate. These results will provide future guidance of therapy for couples with unexplained infertility, and if comparable pregnancy rates are achieved with a substantial reduction in multiple gestations, the public health benefit will be considerable.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ovarian stimulation and intrauterine insemination (OS/IUI), a mainstay of current infertility therapy and a common antecedent to IVF, is a significant driver of the multiple births epidemic. Redress of this challenge, now marking its quarter centennial, will require a rethinking of current practice patterns. Herein we explore prospects for prevention, mitigation, and eventual resolution. We conclude that the multiple births attributable to OS/IUI may not be entirely preventable but that the outlook for their mitigation is promising, if in need of solidification. Specifically, we observe that low-dose (≤ 75 IU) gondotropin, clomiphene, and especially off-label letrozole regimens outperform high-dose (≥ 150 IU) gonadotropin counterparts in the gestational plurality category while maintaining comparable per-cycle pregnancy rates. Accordingly we recommend that, subject to appropriate exceptions, high-dose gonadotropin regimens be used sparingly and that whenever possible they be replaced with emerging alternatives. Finally, we posit that OS/IUI is not likely to be superseded by IVF absent further commoditization and thus greater affordability.
    Fertility and sterility 04/2012; 97(4):802-9. DOI:10.1016/j.fertnstert.2012.02.031 · 4.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The most important outcome of infertility treatment is a birth of a healthy baby. In many countries, in-vitro fertilisation treatments carry a high risk of twin pregnancy, which brings a higher risk to the mother and child than singleton pregnancies. Preterm delivery and low birth weight are the main factors accounting for the excess in neonatal morbidity. The use of elective single embryo transfer combined with cryopreservation can minimise the twin rate. Recent studies have shown that repeat single-embryo transfer can produce more live births per oocyte retrieval than double-embryo transfer. Ovulation-induction treatment protocols can also be improved and optimised. Correct counselling is important, as many infertile couples may desire twin pregnancies. Good counselling should include realistic information on the risks of twin gestation and also on later burdens with a multiple birth.
    Best practice & research. Clinical obstetrics & gynaecology 07/2012; 26(6):829-40. DOI:10.1016/j.bpobgyn.2012.05.011 · 3.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The concept of using aromatase inhibitors in place of clomiphene citrate (CC) for ovulation induction was introduced >10 years ago; a brief history of its development is presented. Its worldwide usage for ovulation induction, including as an adjunct for intrauterine insemination and in vitro fertilization has occurred despite the absence of definitive data of superiority to CC. The results of two ongoing potentially definitive multicenter trials of efficacy and safety of letrozole compared with CC are eagerly awaited.
    Fertility and sterility 12/2012; 98(6):1352-5. DOI:10.1016/j.fertnstert.2012.10.008 · 4.30 Impact Factor